In the BioHarmony Drug Report Database
Neostigmine
Bloxiverz, Neostigmine Methylsulfate (neostigmine) is a small molecule pharmaceutical. Neostigmine was first approved as Bloxiverz on 2013-05-31. It is used to treat drug-induced abnormalities, myasthenia gravis, urinary bladder diseases, and urinary retention in the USA. It is known to target acetylcholinesterase.
Trade Name
|
Bloxiverz, Neostigmine Methylsulfate |
|---|---|
Common Name
|
neostigmine |
ChEMBL ID
|
CHEMBL278020 |
Indication
|
drug-induced abnormalities, myasthenia gravis, urinary bladder diseases, urinary retention |
Drug Class
|
Cholinesterase inhibitors (physostigmine type) |
Image (chem structure or protein)